Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection

Drugs of Today

Volumn 50, Issue 1, 2014, Pages 7-14

  Temesgen, Z ^a   Talwani, R ^b   Rizza, S A ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MARYLAND   (United States)

Author keywords

Anti HIV agents; Antiretroviral naive; Dolutegravir; GSK 1349572; HIV integrase inhibitors

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE ISOENZYME 2; ATAZANAVIR; BILIRUBIN; CREATINE KINASE; CREATININE; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; ELVITEGRAVIR; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETRAVIRINE; FOSAMPRENAVIR; FOSAMPRENAVIR PLUS RITONAVIR; GLUCURONOSYLTRANSFERASE; LOPINAVIR; METHADONE; MIDAZOLAM; NEVIRAPINE; PLACEBO; RALTEGRAVIR; RIFABUTIN; RIFAMPICIN; RILPIVIRINE; RITONAVIR; TELAPREVIR; TENOFOVIR; UNINDEXED DRUG; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; CD4 LYMPHOCYTE COUNT; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; GLUCURONIDATION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LIVER INJURY; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; UNSPECIFIED SIDE EFFECT; VIRUS MUTATION;

EID: 84893656036     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2014.50.1.2097790     Document Type: Review

References (26)

1. Hare, S., Smith, S.J., Metifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S.H., Cherepanov, P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011, 80(4): 565-72.
2. Hightower, K.E., Wang, R., Deanda, F. et al. Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother 2011, 55(10): 4552-9.
3. Dicker, I.B., Samanta, H.K., Li, Z. et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem 2007, 282(43): 31186-96. (Pubitemid 350044860)
4. Dicker, I.B., Terry, B., Lin, Z. et al. Biochemical analysis of HIV-1 integrase variants resistant to strand transfer inhibitors. J Biol Chem 2008, 283(35): 23599-609.
5. Song, I., Min, S.S., Borland, J. et al. Lack of interaction between the HIV integrase inhibitor S/GSK1349572 and tenofovir in healthy subjects. J Acquir Immune Defic Syndr 2010, 55(3): 365-7.
6. Min, S., Song, I., Borland, J., Chen, S., Lou, Y, Fujiwara, T., Piscitelli, S.C. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010, 54(1): 254-8.
7. Kobayashi, M., Yoshinaga, T., Seki, T. et al. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother 2011, 55(2): 813-21.
8. Raffi, F., Rachlis, A., Stellbrink, H.J. et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRINC-2 study. Lancet 2013, 381(9868): 735-43.
9. Walmsley, S.L., Antela, A., Clumeck, N. et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med 2013, 369(19): 1807-18.
10. Feinberg, J., Clotet, B., Khouong, M.-A., et al. Once-daily dolutegravir (DTG) is superior to darunavir/ritonavir (DRV/r) in antiretroviral-naive adults: 48 week results from FLAMINGO (ING114915). 53rd Intersci Conf Antimicrob Agents Chemother (ICAAC) (September 10-13, Denver) 2013, Abst H-1464a.
11. Cahn, P., Pozniak, A.L., Mingrone, H. et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet 2013, 382(9893): 700-8.
12. Nichols, G., Lazzrin, A., Maggiolo, F. et al. Phase 3 assessment of dolutegravir (DTG) 50mg twice daily in HIV-1-infected subjects with raltegravir (RAL) and/or elvitegravir (EVG) resistance in VIKING-3: week 24 results of all 183 patients enrolled. IAS Conf HIV Pathog Treat Prev (June 30-July 3, Kuala Lumpur) 2013, Abst TULBPE19.
13. ViiV Healthcare. Tivcay [package insert]. Research Triangle Park, NC 2013.
14. Dooley, K.E., Sayre, P., Borland, J. et al. Safety tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013, 62(1): 21-7.
15. Song, I., Borland, J., Min, S. et al. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir. Antimicrob Agents Chemother 2011, 55(7): 3517-21.
16. Seki, T., Kobayashi, M., Wakasa-Morimoto, C, et al. S/GSK1349572 is a potent next generation HIV integrase inhibitor and demonstrates a superior resistance profile substantiated with 60 integrase mutant molecular clones. 17th Conf Retrovirus Opportunistic Infect (CROI) (February 16-19, San Francisco) 2010, Abst 555.
17. Sato, A., Kobayashi, M., Seki, T. et al. S/GSK1349572: A next generation integrase inhibitor (INI) with limited or no-cross resistance to first generation INIs or other classes of antivirals. 8th Eur HIV Drug Resist Workshop (March 17-19, Sorrento) 2010, Abst 29.
18. Quashie, P.K., Mesplede, T., Han, Y.S. et al. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol 2012, 86(5): 2696-705.
19. Mesplede, T., Quashie, P.K., Osman, N. et al. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology 2013, 10: 22.
20. Marcelin, A.G., Malet, I., Fabeni, L., et al. Resistance-associated mutations to integrase inhibitor S/GSK1349572 in HIV-1 integrase inhibitornaïve and raltegravir-experienced patients. 17th Conf Retroviruses Opportunistic Infect (CROI) (February 16-19, San Francisco) 2010, Abst 554.
21. Underwood, M.R., Johns, B.A., Sato, A., Martin, J.N., Deeks, S.G., Fujiwara, T. The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults. J Acquir Immune Defic Syndr 2012, 61(3): 297-301.
22. Garrido, C., Soriano, V., Geretti, A.M. et al. Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - impact of HIV subtypes and prior raltegravir experience. Antiviral Res 2011, 90(3): 164-7.
23. Canducci, F., Ceresola, E.R., Boeri, E. et al. Cross-resistance profile of the novel integrase inhibitor Dolutegravir (S/GSK1349572) using clonal viral variants selected in patients failing raltegravir. J Infect Dis 2011, 204(11): 1811-5.
24. Song, I., Borland, J., Chen, S., Patel, P., Wajima, T., Peppercorn, A., Piscitelli, S.C. Effect of food on the pharmacokinetics of the integrase inhibitor dolutegravir. Antimicrob Agents Chemother 2012, 56(3): 1627-9.
25. van Lunzen, J., Maggiolo, F., Arribas, J.R. et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in anti-retroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial. Lancet Infect Dis 2012, 12(2): 111-8.
26. Eron, J.J., Clotet, B., Durant, J. et al. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study. J Infect Dis 2013, 207(5): 740-8.